Clinical pharmacokinetics of meloxicam: A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug

Meloxicam [4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine -3-carboxamide-1, 1-dioxide] is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class which shows preferential inhibition of cyclo-oxygenase-2. Meloxicam has a plasma half-life of approximately 20 hours, making i...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacokinetics 1999-02, Vol.36 (2), p.115-126
Main Authors: DAVIES, N. M, SKJODT, N. M
Format: Article
Language:English
Subjects:
Age Factors
Aged
Anti-Inflammatory Agents, Non-Steroidal - administration & dosage
Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics
Biological and medical sciences
Bones, joints and connective tissue. Antiinflammatory agents
Cyclooxygenase Inhibitors - administration & dosage
Cyclooxygenase Inhibitors - pharmacokinetics
Drug Interactions
Female
Humans
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Thiazines - administration & dosage
Thiazines - pharmacokinetics
Thiazoles - administration & dosage
Thiazoles - pharmacokinetics
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Meloxicam [4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine -3-carboxamide-1, 1-dioxide] is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class which shows preferential inhibition of cyclo-oxygenase-2. Meloxicam has a plasma half-life of approximately 20 hours, making it convenient for once-daily administration. Meloxicam is eliminated after biotransformation to 4 pharmacologically inactive metabolites, which are excreted in urine and faeces. Meloxicam and its metabolites bind extensively to plasma albumin. Substantial concentrations of meloxicam are attained in synovial fluid, the proposed site of action in chronic inflammatory arthropathies. Neither moderate renal nor hepatic insufficiency significantly alter the pharmacokinetics of meloxicam. Dosage adjustment is not required in the elderly. Drug-drug interaction studies are available for some commonly co-prescribed medications. Concentration-dependent therapeutic and toxicological effects have yet to be extensively elucidated for this NSAID.
ISSN:0312-5963
1179-1926
DOI:10.2165/00003088-199936020-00003